Program
Megestrol Acetate
Also written as “Nano-crystalline Megestrol Acetate Oral Suspension”, “Megestrol acetate concentrated suspension 125 mg/mL” and “Megestrol acetate”.
Its studies are mostly in Anorexia · Cachexia · Neoplasms · Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis, led by 6 companies.
Drug pageMegestrol Acetate: every studyMany companies study it; this page follows only the 18 they lead. All 66 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 77 open or running | phase 4since Nov 15, 2025 | Dec 25, 2024 | Dec 31, 2026phase 4 · NCT07243379 |
| Bristol-Myers Squibbits history only | 30 open or running | phase 4since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Par Healthits history only | 30 open or running | phase 3since Mar 11, 2008 | Mar 11, 2008 | none ahead |
| Keenova Therapeuticsits history only | 20 open or running | phase 2since Mar 11, 2008 | Mar 11, 2008 | none ahead |
| Rottapharm Spainits history only | 20 open or running | phase 3since Jul 17, 2007 | Jul 17, 2007 | none ahead |
| TTY Biopharmits history only | 10 open or running | phase 2since Jul 25, 2016 | Jul 25, 2016 | none ahead |
Also a collaborator on its studies: Quintiles, Covance, SFBC Anapharm and PRA Health Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Changchun GeneScience Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 25, 2024First study: phase 3 study in Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk FactorsFirst studyNCT06772428 · 96 planned · China
- Feb 11, 2025No phase study in Cancer-related Fatigue, Gastric Cancer,Colorectal Cancer,Nano-crystalline Megestrol Acetate,Megestrol Acetate,First-line TreatmentNCT06830018 · 76 planned · China
- Apr 29, 20252 phase 3 studiesNCT06961201, NCT06961188
- Aug 25, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07150663 · 134 planned · China
- Nov 15, 2025Phase 4 study in Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaNCT07243379 · 495 planned · China
- Jan 4, 2026Phase 3 study in CachexiaNCT07356037 · 68 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 4 study in Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaNCT07243379
- Dec 31, 2026Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT06961201
- Jun 30, 2027Primary completion: phase 3 study in CachexiaNCT07356037
- Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07150663
TargetBeta
“Progesterone receptor agonist”ChEMBL 37, by rule
Other programs on PGR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Levonorgestrelrule | Bayer | phase 4 | 56 |
| drospirenonerule | estetra | phase 4 | 20 |
| Medroxyprogesterone Acetaterule | Pfizer | phase 4 | 11 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Utrogestanrule | calla-lily-clinical-care-ltd | phase 1 | 1 |
Studies
All 7 Changchun GeneScience Pharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07356037Cachexia · China | 3 | Not yet recruiting | Jun 30, 2027 | 68 |
| NCT07243379Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia · China | 4 | Recruiting | Dec 31, 2026 | 495 |
| NCT07150663Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Jun 30, 2027 | 134 |
| NCT06961201Small Cell Lung Carcinoma · China | 3 | Not yet recruiting | Dec 31, 2026 | 94 |
| NCT06961188Neoplasm Metastasis · China | 3 | Not yet recruiting | Jun 30, 2027 | 174 |
| NCT06830018Cancer-related Fatigue, Gastric Cancer,Colorectal Cancer,Nano-crystalline Megestrol Acetate,Megestrol Acetate,First-line Treatment · China | – | Recruiting | Jan 2026 | 76 |
| NCT06772428Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors · China | 3 | Not yet recruiting | Jun 30, 2027 | 96 |
How it is read
Names in the registry
- “Nano-crystalline Megestrol Acetate Oral Suspension”, 5 entries
- “Megestrol acetate concentrated suspension 125 mg/mL”, 5 entries
- “Megestrol acetate”, 5 entries
- “Nanocrystalline Megestrol Acetate”, 2 entries
- “Megestrol acetate concentrated suspension 110 mg/mL”, 2 entries
Conditions, from the studies’ own filings
- Anorexia, 5 studies
- Cachexia, 2 studies
- Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.